This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Reference
Chaillon A, et al. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLOS One : 6 Jun 2019. Available from: URL: https://doi.org/10.1371/journal.pone.0217964
Rights and permissions
About this article
Cite this article
HCV treatment and annual retesting cost effective in India. PharmacoEcon Outcomes News 831, 18 (2019). https://doi.org/10.1007/s40274-019-6006-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6006-3